Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Lifecycle Trial of dapagliflozin in severe chronic kidney disease
NL-OMON60254Phase 3Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Time to composite endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure. Started Nov 2022; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON60254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60254.